···
Cocktail at the The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia. Fresh lime and club soda. Image details File size:
43.2 MB (1.4 MB Compressed download)
Open your image file to the full size using image processing software.
Dimensions:
4700 x 3216 px | 39.8 x 27.2 cm | 15.7 x 10.7 inches | 300dpi
Date taken:
16 February 2018
Search stock photos by tags
Similar stock images Cocktail at the The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia. Fresh lime and club soda. Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/cocktail-at-the-the-foreign-correspondents-club-in-phnom-penh-capital-of-cambodia-phnom-penh-city-cambodia-fresh-lime-and-club-soda-image182858167.html RM MHDWCR – Cocktail at the The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia. Fresh lime and club soda. Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-japans-drug-maker-chugai-pharmaceutical-president-osamu-okuda-speaks-at-the-foreign-correspondents-club-of-japan-in-tokyo-on-friday-august-27-2021-chugai-a-subsidiary-of-swiss-drug-giant-hoffman-la-roche-provides-an-antibody-cocktail-drug-ronapreve-which-is-developed-by-us-biotechnology-company-regeneron-pharmaceuticals-and-roche-for-the-covid-19-patients-to-japan-through-the-government-credit-yoshio-tsunodaafloalamy-live-news-image440029227.html RM 2GFW1NF – Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19 on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-osamu-okuda-president-ceo-at-chugai-pharmaceutical-co-ltd-held-a-press-conference-at-the-foreign-correspondents-club-of-japan-fccj-chugai-a-subsidiary-of-swiss-drug-maker-hoffmann-la-roche-has-the-rights-to-develop-and-market-the-antibody-cocktail-drug-lonapreve-in-japan-developed-by-us-based-regeneron-pharmaceuticals-and-roche-for-patients-with-covid-19-on-august-27-2021-in-tokyo-japan-photo-by-kazuki-oishisipa-usa-credit-sipa-usaalamy-live-news-image440062000.html RM 2GFXFG0 – Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19 on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-japans-drug-maker-chugai-pharmaceutical-president-osamu-okuda-speaks-at-the-foreign-correspondents-club-of-japan-in-tokyo-on-friday-august-27-2021-chugai-a-subsidiary-of-swiss-drug-giant-hoffman-la-roche-provides-an-antibody-cocktail-drug-ronapreve-which-is-developed-by-us-biotechnology-company-regeneron-pharmaceuticals-and-roche-for-the-covid-19-patients-to-japan-through-the-government-credit-yoshio-tsunodaafloalamy-live-news-image440029339.html RM 2GFW1WF – Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19 on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-osamu-okuda-president-ceo-at-chugai-pharmaceutical-co-ltd-held-a-press-conference-at-the-foreign-correspondents-club-of-japan-fccj-chugai-a-subsidiary-of-swiss-drug-maker-hoffmann-la-roche-has-the-rights-to-develop-and-market-the-antibody-cocktail-drug-lonapreve-in-japan-developed-by-us-based-regeneron-pharmaceuticals-and-roche-for-patients-with-covid-19-on-august-27-2021-in-tokyo-japan-photo-by-kazuki-oishisipa-usa-credit-sipa-usaalamy-live-news-image440062193.html RM 2GFXFPW – Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19 on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News Cocktail at the The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia. Fresh lime and club soda. Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/cocktail-at-the-the-foreign-correspondents-club-in-phnom-penh-capital-of-cambodia-phnom-penh-city-cambodia-fresh-lime-and-club-soda-image182858172.html RM MHDWD0 – Cocktail at the The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia. Fresh lime and club soda. Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-japans-drug-maker-chugai-pharmaceutical-president-osamu-okuda-speaks-at-the-foreign-correspondents-club-of-japan-in-tokyo-on-friday-august-27-2021-chugai-a-subsidiary-of-swiss-drug-giant-hoffman-la-roche-provides-an-antibody-cocktail-drug-ronapreve-which-is-developed-by-us-biotechnology-company-regeneron-pharmaceuticals-and-roche-for-the-covid-19-patients-to-japan-through-the-government-credit-yoshio-tsunodaafloalamy-live-news-image440029301.html RM 2GFW1T5 – Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19 on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-osamu-okuda-president-ceo-at-chugai-pharmaceutical-co-ltd-held-a-press-conference-at-the-foreign-correspondents-club-of-japan-fccj-chugai-a-subsidiary-of-swiss-drug-maker-hoffmann-la-roche-has-the-rights-to-develop-and-market-the-antibody-cocktail-drug-lonapreve-in-japan-developed-by-us-based-regeneron-pharmaceuticals-and-roche-for-patients-with-covid-19-on-august-27-2021-in-tokyo-japan-photo-by-kazuki-oishisipa-usa-credit-sipa-usaalamy-live-news-image440062297.html RM 2GFXFXH – Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19 on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/the-foreign-correspondents-club-in-phnom-penh-capital-of-cambodia-phnom-penh-city-cambodia-image182858159.html RM MHDWCF – The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-japans-drug-maker-chugai-pharmaceutical-president-osamu-okuda-speaks-at-the-foreign-correspondents-club-of-japan-in-tokyo-on-friday-august-27-2021-chugai-a-subsidiary-of-swiss-drug-giant-hoffman-la-roche-provides-an-antibody-cocktail-drug-ronapreve-which-is-developed-by-us-biotechnology-company-regeneron-pharmaceuticals-and-roche-for-the-covid-19-patients-to-japan-through-the-government-credit-yoshio-tsunodaafloalamy-live-news-image440029226.html RM 2GFW1NE – Tokyo, Japan. 27th Aug, 2021. Japan's drug maker Chugai Pharmaceutical president Osamu Okuda speaks at the Foreign Correspondents' Club of Japan in Tokyo on Friday, August 27, 2021. Chugai, a subsidiary of Swiss drug giant Hoffman-La Roche provides an antibody cocktail drug 'Ronapreve' which is developed by U.S. biotechnology company Regeneron Pharmaceuticals and Roche for the COVID-19 patients to Japan through the government. Credit: Yoshio Tsunoda/AFLO/Alamy Live News Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19. Lecture with slides. on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/tokyo-japan-27th-aug-2021-osamu-okuda-president-ceo-at-chugai-pharmaceutical-co-ltd-held-a-press-conference-at-the-foreign-correspondents-club-of-japan-fccj-chugai-a-subsidiary-of-swiss-drug-maker-hoffmann-la-roche-has-the-rights-to-develop-and-market-the-antibody-cocktail-drug-lonapreve-in-japan-developed-by-us-based-regeneron-pharmaceuticals-and-roche-for-patients-with-covid-19-lecture-with-slides-on-august-27-2021-in-tokyo-japan-photo-by-kazuki-oishisipa-usa-credit-sipa-usaalamy-live-news-image440062401.html RM 2GFXG29 – Tokyo, Japan. 27th Aug, 2021. Osamu Okuda, President & CEO at Chugai Pharmaceutical Co., Ltd. held a press conference at the Foreign Correspondents' Club of Japan (FCCJ). Chugai, a subsidiary of Swiss drug maker Hoffmann-La Roche, has the rights to develop and market the antibody cocktail drug 'Lonapreve' in Japan, developed by US-based Regeneron Pharmaceuticals and Roche, for patients with COVID-19. Lecture with slides. on August 27, 2021 in Tokyo, Japan. (Photo by Kazuki Oishi/Sipa USA) Credit: Sipa USA/Alamy Live News The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia Stock Photo https://www.alamy.com/image-license-details/?v=1 https://www.alamy.com/the-foreign-correspondents-club-in-phnom-penh-capital-of-cambodia-phnom-penh-city-cambodia-image182858177.html RM MHDWD5 – The Foreign Correspondents' Club in Phnom Penh, capital of Cambodia, Phnom Penh city, Cambodia 
